🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Primary Central Nervous System Lymphoma

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a1 site📍 Sioux Falls Sanford Health Pembrolizumab, Ibrutinib and Rituximab in PCNSL NCT04421560Phase 1, Phase 24 sites📍 Boston📍 Boston📍 New York Dana-Farber Cancer Institute · Tests: Ibrutinib, Pembrolizumab, Rituximab The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients. NCT05931328Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: thiotepa combined with pomalidomide IGNITE: Study of Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) NCT07104032Phase 342 sites📍 Phoenix📍 Scottsdale📍 Fullerton Ono Pharmaceutical Co., Ltd. · Tests: Tirabrutinib, Rituximab, Temozolomide Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas NCT05681195Phase 21 site📍 Miami Baptist Health South Florida · Tests: Pemetrexed, Zanubrutinib, Autologous Stem Cell Transplant (ASCT), Whole Brain Radiation Therapy (WBRT) Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma NCT04961515Phase 21 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: Orelabrutinib, Sintilimab, Temozolomide (TMZ) NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL NCT06737250Phase 210 sites📍 Busan📍 Hwasun📍 Ilsan NOBO Medicine · Tests: R2P -> RP Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma NCT05260619Phase 21 site📍 Seongnam-si Seoul National University Bundang Hospital · Tests: lenalidomide Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL NCT07749365Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: hypofractionated radiotherapy plus GM-CSF, pomalidomide and glofitamab Cognitive Screening Made Easy for PCPs - Administrative Supplement NCT06928298NA3 sites📍 Austin📍 Austin📍 San Antonio University of Texas at Austin · Tests: RACS app T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) NCT06343311Phase 1, Phase 25 sites📍 Sacramento📍 Cleveland📍 Portland Estrella Immunopharma, Inc. · Tests: EB103 Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL. NCT04627753Phase 21 site📍 Seoul Kim, Seok Jin · Tests: Rituximab, lenalidomide Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies NCT05011045n/a1 site📍 Houston M.D. Anderson Cancer Center · Tests: Magnetic Resonance Imaging, Neurocognitive Assessment, Quality-of-Life Assessment, Questionnaire Administration Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL NCT02836158Phase 2, Phase 31 site📍 Beijing Navy General Hospital, Beijing · Tests: R-IDARAM plus intrathecal chemotherapy Diagnosis; Objective RespOnse; THErApy NCT05036564NA1 site📍 Milan IRCCS San Raffaele · Tests: Lumbar puncture A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137Phase 116 sites📍 Duarte📍 Orange📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-2127 Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma NCT07416890Phase 21 site📍 Hangzhou Zhejiang Cancer Hospital · Tests: Thiotepa, Pirtobrutinib , Sintilimab(TPS) A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL) NCT07137494Phase 17 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: MB-CART19.1 Cellular Therapy Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL NCT07185373Phase 2, Phase 315 sites📍 Beijing📍 Beijing📍 Chengdu Huashan Hospital · Tests: Teniposide, Orelabrutinib, MTX, Rituximab (R), Dexamethasone Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma NCT05351593Phase 1, Phase 21 site📍 San Francisco James Rubenstein · Tests: Tafasitamab, Lenalidomide Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma NCT07188077n/a1 site📍 Fuzhou Ting YANG Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study NCT07002099Phase 21 site📍 Suzhou Second Affiliated Hospital of Soochow University · Tests: Selinexor + High-dose Methotrexate + Rituximab + WBRT Improving Safety and Accuracy of Stereotactic Brain Biopsies in Primary Central Nervous System Lymphoma. NCT06263361n/a1 site📍 Milan IRCCS San Raffaele · Tests: MRI imaging, Cerebral biopsy Phase Ib Clinical Study of Keynatinib NCT04807881Phase 14 sites📍 Beijing📍 Beijing📍 Shanghai Medolution Ltd. · Tests: Keynatinib A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma NCT06554561Phase 1, Phase 21 site📍 Hanzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: Pomalidomide, Rituximab, Methotrexate A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) NCT07082868Phase 18 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: ibrutinib, Epcoritamab Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma NCT07523737Phase 21 site📍 Beijing Beijing Tongren Hospital · Tests: Pomalidomide, PD-1 / PD-L1 monoclonal antibody, XPO1 inhibitor Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810Phase 12 sites📍 Scottsdale📍 Rochester Mayo Clinic · Tests: Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response NCT06175000Phase 27 sites📍 New York📍 Cleveland📍 Portland Providence Health & Services · Tests: Cognitive Assessment, Obinutuzumab, Quality of Life Assessment Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). NCT06213636Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: CD19/CD22-CAR T cells
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy